Experience with sorafenib in the treatment of advanced renal cell carcinoma

Area of Science:

• Oncology
• Pharmacology

Background:

• Sorafenib is the first molecular-targeted agent for advanced/metastatic renal cell carcinoma (RCC).
• RCC was previously refractory to conventional therapies.
• Clinical experience has expanded sorafenib use to other RCC settings and risk populations.

Purpose of the Study:

• To review evidence on the most effective and safe use of sorafenib.
• To focus on sorafenib administration in patients with comorbidities and frail older adults.

Main Methods:

• Literature review of clinical practice and investigations.
• Evidence synthesis on sorafenib efficacy and safety.

Main Results:

• Sorafenib demonstrates efficacy in slowing advanced/metastatic RCC progression.
• Its use is extended to diverse patient groups, including those with comorbidities.
• Careful administration is crucial for patients with impaired organ function.

Conclusions:

• Sorafenib is a key treatment for advanced/metastatic RCC.
• Evidence supports its use in specific patient populations with careful consideration of comorbidities.
• Optimizing sorafenib use requires attention to patient-specific factors like renal and cardiac function and frailty.